{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:58:55Z","timestamp":1789657135359,"version":"4.0.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Familial eosinophilia (FE) is an autosomal dominant disorder characterized by marked eosinophilia and progression to end organ damage in some, but not all, affected family members. To better define the pathogenesis of FE, 13 affected and 11 unaffected family members (NLs) underwent a detailed clinical evaluation at the National Institutes of Health (NIH). No clinical abnormalities were more frequent in the family members with FE compared with the NLs. There was, however, a decreased prevalence of asthma in family members with FE compared with unaffected family members. Eosinophil morphology as assessed by either light or transmission electron microscopy was normal in family members with and without FE. Although levels of eosinophil-derived neurotoxin (EDN) and major basic protein (MBP) were elevated in patients with FE compared with NL, levels of both granule proteins were lower than in nonfamilial hypereosinophilic syndrome (HES). Similarly, increased surface expression of the activation markers CD69, CD25, and HLA-DR was detected by flow cytometry on eosinophils from patients with FE compared with NL, albeit less than that seen in HES. These data suggest that, despite prolonged marked eosinophilia, FE can be distinguished from HES by a more benign clinical course that may be related to a relative lack of eosinophil activation.<\/jats:p>","DOI":"10.1182\/blood-2003-11-3850","type":"journal-article","created":{"date-parts":[[2004,3,2]],"date-time":"2004-03-02T01:45:31Z","timestamp":1078191931000},"page":"4050-4055","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Familial eosinophilia: a benign disorder?"],"prefix":"10.1182","volume":"103","author":[{"given":"Amy D.","family":"Klion","sequence":"first","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Law","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Riemenschneider","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"McMaster","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McDonald","family":"Horne","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Karp","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Robinson","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Sachdev","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eben","family":"Tucker","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Turner","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Nutman","sequence":"additional","affiliation":[{"name":"From the National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, National Cancer Institute, National Eye Institute, National Institute of Neurologic Diseases and Stroke, and the Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223581863600_REF1","doi-asserted-by":"crossref","unstructured":"Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83: 2759-2779.","DOI":"10.1182\/blood.V83.10.2759.2759"},{"key":"2020021223581863600_REF2","doi-asserted-by":"crossref","unstructured":"Chusid MJ, David DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975;54: 1-27.","DOI":"10.1097\/00005792-197501000-00001"},{"key":"2020021223581863600_REF3","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348: 1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"2020021223581863600_REF4","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101: 4660-4666.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"2020021223581863600_REF5","doi-asserted-by":"crossref","unstructured":"Aractingi S, Janin A, Zini JM, et al. Specific mucosal erosions in the hypereosinophilic syndrome: evidence for eosinophil protein deposition. Arch Dermatol. 1996;132: 535-541.","DOI":"10.1001\/archderm.1996.03890290069009"},{"key":"2020021223581863600_REF6","doi-asserted-by":"crossref","unstructured":"Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. The idiopathic hypereosinophilic syndrome. Ann Intern Med. 1982;97: 78-92.","DOI":"10.7326\/0003-4819-97-1-78"},{"key":"2020021223581863600_REF7","doi-asserted-by":"crossref","unstructured":"Tai P, Spry CJF, Olsen EGJ, Ackerman SJ, Dunnette S, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987; 1: 643-647.","DOI":"10.1016\/S0140-6736(87)90412-0"},{"key":"2020021223581863600_REF8","doi-asserted-by":"crossref","unstructured":"Lin AY, Nutman TB, Kaslow D, et al. Familial eosinophilia: clinical and laboratory results on a U.S. kindred. Am J Med Genet. 1998;76: 229-237.","DOI":"10.1002\/(SICI)1096-8628(19980319)76:3<229::AID-AJMG6>3.0.CO;2-L"},{"key":"2020021223581863600_REF9","doi-asserted-by":"crossref","unstructured":"Rioux JD, Stone VA, Daly MJ, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998;63: 1086-1094.","DOI":"10.1086\/302053"},{"key":"2020021223581863600_REF10","doi-asserted-by":"crossref","unstructured":"Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341: 1112-1120.","DOI":"10.1056\/NEJM199910073411503"},{"key":"2020021223581863600_REF11","doi-asserted-by":"crossref","unstructured":"Allanson JE. Objective techniques for craniofacial assessment: what are the choices? Am J Med Genet. 1997;70: 1-5.","DOI":"10.1002\/(SICI)1096-8628(19970502)70:1<1::AID-AJMG1>3.0.CO;2-3"},{"key":"2020021223581863600_REF12","unstructured":"Farkas LG. Anthropometry of the Head and Face. 2nd ed. New York, NY: Raven Press; 1994."},{"key":"2020021223581863600_REF13","doi-asserted-by":"crossref","unstructured":"Garn SM, Smith BH, La Velle M. Applications of pattern profile analysis to malformations of the head and face. Radiology. 1984;50: 683-690.","DOI":"10.1148\/radiology.150.3.6695067"},{"key":"2020021223581863600_REF14","doi-asserted-by":"crossref","unstructured":"Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol. 1991;147: 3490-3495.","DOI":"10.4049\/jimmunol.147.10.3490"},{"key":"2020021223581863600_REF15","doi-asserted-by":"crossref","unstructured":"Peters MS, Gleich GJ, Dunnette SL, Fukuda T. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. Blood, 1988;71: 780-785.","DOI":"10.1182\/blood.V71.3.780.780"},{"key":"2020021223581863600_REF16","doi-asserted-by":"crossref","unstructured":"Dvorak AM, Weller PF. Ultrastructural analysis of human eosinophils. Chem Immunol. 2000;76: 1-28.","DOI":"10.1159\/000058790"},{"key":"2020021223581863600_REF17","doi-asserted-by":"crossref","unstructured":"Bochner BS. Systemic activation of basophils and eosinophils: markers and consequences. J Allergy Clin Immunol. 2000;106: S292-S302.","DOI":"10.1067\/mai.2000.110164"},{"key":"2020021223581863600_REF18","doi-asserted-by":"crossref","unstructured":"Tachimoto H, Bochner BS. The surface phenotype of human eosinophils. Chem Immunol. 2000; 76: 45-62.","DOI":"10.1159\/000058780"},{"key":"2020021223581863600_REF19","doi-asserted-by":"crossref","unstructured":"Wassom DL, Loegering DA, Solley GO, et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest. 1981;67: 651-661.","DOI":"10.1172\/JCI110080"},{"key":"2020021223581863600_REF20","doi-asserted-by":"crossref","unstructured":"Owen WF, Rothenberg ME, Petersen J, et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med. 1989;170: 343-348.","DOI":"10.1084\/jem.170.1.343"},{"key":"2020021223581863600_REF21","doi-asserted-by":"crossref","unstructured":"Committee TISoAaAiCIS. Worldwide variation in the prvalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet. 1998;351: 1225-1232.","DOI":"10.1016\/S0140-6736(97)07302-9"},{"key":"2020021223581863600_REF22","unstructured":"Bobbio-Pallavicini E, Confalonieri M, Tacconi F, et al. Study of release of eosinophil cationic proteins (ECP and EPX) in the hypereosinophilic syndrome (HES) and other hypereosinophilic conditions. Panminerva Med. 1998;40: 186-190."},{"key":"2020021223581863600_REF23","doi-asserted-by":"crossref","unstructured":"Mawhorter SD, Stephany DA, Ottesen EA, Nutman TB. Identification of surface molecules associated with physiologic activation of eosinophils: application of whole blood flow cytometry to eosinophils. J Immunol. 1996;156: 4851-4858.","DOI":"10.4049\/jimmunol.156.12.4851"},{"key":"2020021223581863600_REF24","unstructured":"Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology. 1993;80: 281-286."},{"key":"2020021223581863600_REF25","doi-asserted-by":"crossref","unstructured":"Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils. Am J Resp Cell Mol Biol. 1998;18: 860-866.","DOI":"10.1165\/ajrcmb.18.6.3159"},{"key":"2020021223581863600_REF26","doi-asserted-by":"crossref","unstructured":"Nopp A, Lundahl J, Hallden G. Quantitative, rather than qualitative, differences in CD69 up-regulation in human blood eosinophils upon activation with selected stimuli. Allergy. 2000;55: 148-156.","DOI":"10.1034\/j.1398-9995.2000.00363.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/11\/4050\/1697545\/zh801104004050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/11\/4050\/1697545\/zh801104004050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T01:39:41Z","timestamp":1682645981000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/11\/4050\/17880\/Familial-eosinophilia-a-benign-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-11-3850","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}